![Peter Olagunju](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Olagunju
Chief Executive Officer at
ImmunoSCAPE Pte Ltd.
Profile
Mr. Peter Olagunju is a Chief Executive Officer at ImmunoScape Pte Ltd. and a Chairman at March Biosciences, Inc. Mr. Olagunju was previously employed as a Chief Operating Officer by TCR² Therapeutics, Inc., a Senior Vice President-Technical Operations by FerGene, Inc., a Vice President-Global Patient Operations by bluebird bio, Inc., a Head-Quality by Dendreon Corp., and a Head-Quality by ZymoGenetics, Inc. He received his undergraduate degree from the University of Illinois At Urbana–Champaign and an MBA from Foster School of Business.
Peter Olagunju active positions
| Companies | Position | Start |
|---|---|---|
ImmunoSCAPE Pte Ltd.
 ImmunoSCAPE Pte Ltd. BiotechnologyHealth Technology Operates as a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T cell therapies | Chief Executive Officer | 2026-09-22 |
Former positions of Peter Olagunju
| Companies | Position | End |
|---|---|---|
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Corporate Officer/Principal | 2021-06-30 |
| GENETIX BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 2020-02-29 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Corporate Officer/Principal | - |
| DENDREON CORPORATION | Corporate Officer/Principal | - |
| TCR2 THERAPEUTICS INC. | Chief Operating Officer | - |
Training of Peter Olagunju
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
51
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Discovers, develops and commercializes novel products for the treatment of cancer | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Health Technology |
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
University of Illinois At Urbana–Champaign
 University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ImmunoSCAPE Pte Ltd.
ImmunoSCAPE Pte Ltd. BiotechnologyHealth Technology Operates as a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T cell therapies | Health Technology |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Health Technology |
Foster School of Business
 Foster School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- Peter Olagunju
